Quantification software VueBox® is a Bracco-patented, general-purpose software application for quantifying tissue perfusion using Dynamic Contrast-Enhanced Ultrasound (DCE-US).

Bracco è Marchio Storico di Interesse Nazionale L’azienda, nata nel 1927 e oggi leader globale nella diagnostica per immagini, entra a far parte dell’esclusivo gruppo di imprese storiche che rappresentano la punta di diamante del Made in Italy.

Our New Iodine Recollection Pilot and Re.Viva Re.Viva works to capture and redeploy used substances in the positive momentum of the circular economy: the Bracco Iodine Recollection Pilot 

Unlocking the AI Revolution Diana Bracco: “Artificial Intelligence will assist radiologists in making increasingly accurate and reliable diagnoses”

Bracco Imaging announces global agreement with Subtle Medical Industry Leaders to Explore the Potential of AI in Contrast-Enhanced MRI.

Vueway® (Gadopiclenol) Receives Positive CHMP Opinion The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of the macrocyclic, high-relaxivity Gadopiclenol in adults and pediatric patients older than 2 years of age.

Bracco group celebrates twenty years of Bracco Spin During the conference “Sustainability, growth, employment: The Torviscosa model,” Bracco announced the plan to expand production capacity at its Torviscosa plant to meet the increasing demand for X-ray contrast agents, and will be making new hires

Diana Bracco: “we put people at the heart of sustainable development” During the conference "Sustainability, growth, employment: the Torviscosa model,” the Bracco Group presented its new Sustainability Report. The Report enumerates all the actions that Bracco, global leader in diagnostic imaging, has taken in favour of people, the planet and innovation.

Bracco announces long term strategic partnership with ulrich medical The partnership will bring a Bracco branded state of the art MR injector to the United States under an exclusive private label arrangement.

The EC granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union Vueway®, a new macrocyclic gadolinium-based contrast agent for CE-MRI, received Marketing Authorisation in the European Union By European Commission.